United States (Change Country)
1 Product Citation(s)
E7080 (Lenvatinib) Chemical Structure
E7080 (Lenvatinib) is the most potent dual inhibitor of VEGF-R3 tyrosine kinase (IC50=5.2 nM) as well as VEGF-R2 tyrosine kinase (IC50=4.0 nM) among those small-molecule inhibitors of VEGF-R kinases, such as sunitinib, sorafenib, and CEP-7055. It has been evaluated in vitro (pre-clinical) for anti-cancer effects. E7080 (Lenvatinib) suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of angiogenesis and lymphangiogenesis. [2,3]
It has had promising results from a phase I clinical trial in 2006 and is being tested in several Phase I and II trials as of October 2009, for example against hepatocellular carcinoma and non-small cell lung carcinoma. [1]
[1] Clin Cancer Res 2009;15:7229-7237
[2] Clin Cancer Res 2008;14:5459-5465
[3] Int. J. Cancer 2008;122:664–671
| Molecular Weight (WM): | 426.85 |
|---|---|
| Formula: | C21H19ClN4O4 |
| Solubility(R.T.:25°C): | DMSO 40mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL |
A collection of 715 inhibitors
A collection of 271 kinase inhibitors
A collection of 785 FDA approved drugs
A collection of 144 natural products
A collection of 84 chemotherapeutic agents
A collection of 1463 bioactive compounds
A collection of 117 tyrosine kinase inhibitors
Keywords:buy E7080 (Lenvatinib) | E7080 (Lenvatinib) supplier | purchase E7080 (Lenvatinib) | E7080 (Lenvatinib) cost | E7080 (Lenvatinib) manufacturer | order E7080 (Lenvatinib) | E7080 (Lenvatinib) distributor